Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) Stock Gains Momentum: What’s The Buzz?

Clinical stage biotech firm Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) was in focus among investors and saw its stock end the day with gains of as much as 4%. The company was actually in the news yesterday after it made an announcement with regards to the clinical trial of its cancer immunotherapy product PV 10. The trial is currently ongoing for the same.

Market Reaction

On Tuesday , PVCT stock gained 3.85% to $0.0675 with 211K shares, compared to its average volume of 286K shares. The stock has moved within a range of $0.0622 – 0.0675 after opening trade at $0.0622.

Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation

Provectus announced yesterday that the data from the trial is going to be presented at the European Neuroendocrine Tumor Society conference that is going to be held from March 10 to March 11 this year in Barcelona, Spain. It should be noted that the event is also going to be available online.

The news about the company making a presentation at the key industry event led to a degree of optimism about the stock and that was possibly the reason behind the rally yesterday. The company is going to be involved in the presentation of an abstract that is titled “Phase 1 study of Intralesional (IL) rose bengal (PV-10), an investigational autolytic immunotherapy”. At this point it may be a good idea for invesors to keep an eye on the stock for the rest of the week.

Traders Review

PVCT stock is trading above the 20-Day and 50-Day Moving averages of $0.0645 and $0.0584 respectively. Moreover, the stock is trading above the 200-Day moving average of $0.0632.


Leave a Reply

Your email address will not be published.